Annals of Oncology 14:123-130, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease
1 Department of Medicine, Division of Medical Oncology and Hematology and 2 Division of Nuclear Medicine, University of Liège, Liège, Belgium
Received 18 February 2002; revised 4 June 2002; accepted 17 July 2002
Background:
Relapse after treatment of Hodgkin’s disease (HD) is usually identified as a result of the investigation of symptoms. We undertook this study to examine the value of whole-body positron emission tomography (PET) for the detection of preclinical relapse.
Patients and methods:
Thirty-six patients underwent 2-[fluorine-18]fluoro-2-deoxy-D-glucose (18F-FDG) PET at the end of treatment and than every 4–6 months for 2–3 years after the end of polychemotherapy and/or radiotherapy. In those cases of abnormal 18F-FDG accumulation a confirmatory study was performed 4–6 weeks later.
Results:
One patient had residual tumor and four patients relapsed during a follow-up of 5–24 months. All five events were correctly identified early by 18F-FDG PET. Residual tumor or relapse was never first diagnosed based on clinical examination, laboratory findings or computed tomography (CT) studies. Two patients presented B symptoms and the three others were asymptomatic at the time of residual disease or relapse. Confirmation of residual disease or relapse was obtained by biopsy in four patients 1, 1, 5 and 9 months after PET and by unequivocal clinical symptoms and CT studies in one patient 3 months after PET. False-positive 18F-FDG PET studies incorrectly suggested possible relapse in six other patients, but the confirmatory PET was always negative. Our study also provides important information about physiological 18F-FDG uptake in the thymus.
Conclusions:
Our data suggest the potential of 18F-FDG PET to detect preclinical relapse in patients with HD. This could help identify patients requiring salvage chemotherapy at the time of minimal disease rather than at the time of clinically overt relapse. Further studies are warranted to determine the impact of PET on treatment management and outcome. In fact, the aim of follow-up procedures is not only to detect preclinical relapse but mainly to obtain better results by starting salvage treatment earlier. A cost–benefit analysis will also be necessary before 18F-FDG PET can be used routinely in the follow-up of patients with HD.
Key-words: 2-[fluorine-18]fluoro-2-deoxy-D-glucose, follow-up, Hodgkin’s disease, positron emission tomography, radionuclide imaging, relapse
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Petrausch, P. Samaras, P. Veit-Haibach, A. Tschopp, J. D. Soyka, A. Knuth, T. F. Hany, A. Mischo, C. Renner, and N. G. Schaefer Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann. Onc., November 13, 2009; (2009) mdp519v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mocikova, P. Obrtlikova, B. Vackova, and M. Trneny Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study Ann. Onc., November 9, 2009; (2009) mdp522v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Sher, P. M. Mauch, A. Van Den Abbeele, A. S. LaCasce, J. Czerminski, and A. K. Ng Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy Ann. Onc., November 1, 2009; 20(11): 1848 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jerushalmi, A. Frenkel, R. Bar-Shalom, J. Khoury, and O. Israel Physiologic Thymic Uptake of 18F-FDG in Children and Young Adults: A PET/CT Evaluation of Incidence, Patterns, and Relationship to Treatment J. Nucl. Med., June 1, 2009; 50(6): 849 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Luigi Zinzani, V. Stefoni, M. Tani, S. Fanti, G. Musuraca, P. Castellucci, E. Marchi, M. Fina, V. Ambrosini, C. Pellegrini, et al. Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma J. Clin. Oncol., April 10, 2009; 27(11): 1781 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Terasawa, T. Nihashi, T. Hotta, and H. Nagai 18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review J. Nucl. Med., January 1, 2008; 49(1): 13 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Griffin, M. E. Gore, and S. A. Sohaib Imaging in Metastatic Renal Cell Carcinoma Am. J. Roentgenol., August 1, 2007; 189(2): 360 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al. Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Zinzani, M. Tani, R. Trisolini, S. Fanti, V. Stefoni, M. Alifano, P. Castellucci, G. Musuraca, G. Dalpiaz, L. Alinari, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma Haematologica, June 1, 2007; 92(6): 771 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al. Revised Response Criteria for Malignant Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al. Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Res., November 15, 2006; 66(22): 11055 - 11061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Guadagnolo, R. S. Punglia, K. M. Kuntz, P. M. Mauch, and A. K. Ng Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease J. Clin. Oncol., September 1, 2006; 24(25): 4116 - 4122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Armitage and F. R. Loberiza Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? Ann. Onc., June 1, 2006; 17(6): 883 - 884. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Juweid Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 259 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Juweid and B. D. Cheson Role of Positron Emission Tomography in Lymphoma J. Clin. Oncol., July 20, 2005; 23(21): 4577 - 4580. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls RadioGraphics, January 1, 2005; 25(1): 191 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Munker, J. Glass, L. K. Griffeth, T. Sattar, R. Zamani, M. Heldmann, R. Shi, and D. L. Lilien Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease Ann. Onc., November 1, 2004; 15(11): 1699 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Meyer, R. F. Ambinder, and S. Stroobants Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice Hematology, January 1, 2004; 2004(1): 184 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Friedberg and V. Chengazi PET Scans in the Staging of Lymphoma: Current Status Oncologist, October 1, 2003; 8(5): 438 - 447. [Abstract] [Full Text] [PDF]
|
|